Type 2 Diabetes Mellitus Market Trends to 2021 in Developed Markets 2

Get 25% Discount on Corporate Licence of Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 – Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth Market Research Report at –http://www.absolutereports.com/enquiry/request-discount/10070556 Offer valid till 1st July 2016 Scope of the report: – Metformin monotherapy will remain the first-line pharmacotherapy for T2DM. – The emergence of several new drug classes over the past decade, namely the Glucagon-Like Peptide-1 (GLP-1) receptor agonists, Dipeptidyl Peptidase 4 (DPP4) inhibitors, and Sodium–Glucose Cotransporter 2 (SGLT-2) inhibitors, has led to considerable market growth. – Which products lead these drug classes and what threats do they face from the pipeline? – How will the continued uptake of newer drug classes impact established drug classes such as the sulfonylureas and thiazolidinediones? – Leading insulin therapy Lantus (insulin glargine) recently lost patent protection in most major markets. – Will recently approved insulin therapies such as Tresiba (insulin degludec) and Toujeo (insulin glargine) be able to capture a significant portion of Lantus’ market share? – The pipeline is large and highly innovative, comprising a range of molecule types and molecular targets. – How do different molecule types and molecular targets compare in terms of average failure rate, clinical trial duration, and clinical trial size? – Which late-stage pipeline molecules show the most promise and how will they impact the treatment algorithm over the forecast period? – Which late-stage pipeline molecules are expected to generate the highest revenues? – Over the 2014–2021 forecast period, the global T2DM market is expected to increase in value at a CAGR of 7.5% from $23.5 billion to $39.0 billion. – How do prevalence, diagnosis, and treatment patterns vary in the eight major markets? – Which factors will drive market growth most significantly? – Strategic consolidation activity in T2DM is considerable, with US-based companies being key players. – Do T2DM products tend to attract high levels of investment? Request sample PDF of Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 – Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth Market Research Report at-http://www.absolutereports.com/enquiry/request-sample/10070556 How helpful is the report?

Type 2 Diabetes Mellitus Market Trends to 2021 in Developed Markets 2 | Page 2